• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Editas Medicine, Inc. - Common Stock (NQ: EDIT )

    1.205 -0.005 (-0.41%)
    Streaming Delayed Price Updated: 11:13 AM EST, Dec 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 872,711
    Open 1.190
    Bid (Size) 1.200 (43)
    Ask (Size) 1.210 (210)
    Prev. Close 1.210
    Today's Range 1.160 - 1.220
    52wk Range 1.200 - 11.58
    Shares Outstanding 81,632,619
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    JPMorgan Downgrades Editas Medicine, Says Focus Shift Sparks Investor Caution
    Editas Medicine pivots to in vivo gene editing, extends cash runway to 2027, but faces investor caution amid unclear proof-of-concept timelines. 
    Via Benzinga
    Walmart To Rally Over 22%? Here Are 10 Top Analyst Forecasts For Friday
    Via Benzinga

    Performance

    YTD
    -87.93%
    -87.93%
    1 Month
    -49.37%
    -49.37%
    3 Month
    -64.45%
    -64.45%
    6 Month
    -74.95%
    -74.95%
    1 Year
    -88.70%
    -88.70%

    More News

    Read More
    This Toll Brothers Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
    Via Benzinga
    Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026
    Via Benzinga
    Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
    From Editas Medicine, Inc.
    Via GlobeNewswire
    12 Analysts Have This To Say About Editas Medicine
    Via Benzinga
    Expert Outlook: Editas Medicine Through The Eyes Of 7 Analysts
    Via Benzinga
    Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
    From Editas Medicine, Inc.
    Via GlobeNewswire
    Wall Street's Top 10 Stock Calls This Week - Saturday, Nov. 30
    Via Talk Markets
    Topics Stocks / Equities
    Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts
    Via Benzinga
    Editas Medicine to Participate in Upcoming Investor Conferences
    From Editas Medicine, Inc.
    Via GlobeNewswire
    Where Editas Medicine Stands With Analysts
    Via Benzinga
    Editas Medicine Announces Third Quarter 2024 Results and Business Updates
    From Editas Medicine, Inc.
    Via GlobeNewswire
    Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
    From Editas Medicine, Inc.
    Via GlobeNewswire
    Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
    From Editas Medicine, Inc.
    Via GlobeNewswire
    Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
    From Editas Medicine, Inc.
    Via GlobeNewswire
    Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
    From Editas Medicine, Inc.
    Via GlobeNewswire
    Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
    Via Investor's Business Daily
    Looking for Stock Bargains With Room to Run? Try This.
    Via The Motley Fool
    Editas Medicine to Participate in Upcoming Investor Conferences
    From Editas Medicine, Inc.
    Via GlobeNewswire
    Boot Barn To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga
    Editas Medicine Announces Second Quarter 2024 Results and Business Updates
    From Editas Medicine, Inc.
    Via GlobeNewswire
    Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
    From Editas Medicine, Inc.
    Via GlobeNewswire
    3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
    Via InvestorPlace
    3 Profitable CRISPR Stocks Earning Analysts’ Praise
    Via InvestorPlace
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.